Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT02809456
Other study ID # N201508038
Secondary ID
Status Enrolling by invitation
Phase Phase 2
First received June 9, 2016
Last updated June 22, 2016
Start date July 2016
Est. completion date December 2019

Study information

Verified date June 2016
Source Taipei Medical University WanFang Hospital
Contact n/a
Is FDA regulated No
Health authority Taipei Medical University: Taiwan, R.O.C
Study type Interventional

Clinical Trial Summary

This project will test the effect of nicorandil to mitigate the lung damage that can occur as a side effect of radiation therapy for lung cancer. Thousands of veterans develop lung cancer every year, and are treated by radiation therapy. Studies of lung radiation injury in laboratory animals show that with nicorandil, investigators can significantly reduce the severity of lung fibrosis and heart toxicity.1,2 Nicorandil is FDA approved and in common use for treatment of angina. These studies will advance that work to human use. Successful mitigation of lung radiation damage and heart toxicity will improve the quality of life in veterans and non-veterans who are treated for lung cancer by radiation, and may also improve cure rates of radiation therapy for lung cancer.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 50
Est. completion date December 2019
Est. primary completion date July 2019
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria:

1. Histologically or cytologically-proven NSCLC; mixed histology with small cell lung carcinoma (SCLC) component not allowed

2. Patients with stage II - IV NSCLC who received at least 54 Gy of total planned thoracic radiation dose will be eligible; patients must have received at least one cycle of chemotherapy concurrently during the course of thoracic radiation; regimens allowed are platinum combinations with either etoposide or a taxane regardless of histology subtype; platinum with pemetrexed for patients with nonsquamous NSCLC only; patients with oligometastatic stage IV cancer are eligible if they have received only one line of systemic therapy for their stage IV cancer prior to the concurrent chemoradiation phase

3. Patient must have had a CR/PR/SD, 4-6 weeks after completing last fraction of chemotherapy / radiation therapy.

4. Eastern Cooperative Oncology Group (ECOG) performance score 0-2 at the time of randomization

5. Absolute neutrophil count (ANC) >= 1,500/uL

6. Platelet count >= 100,000/uL

7. Hemoglobin >= 9 g/dL

8. Total bilirubin =< 1.5 times upper limit of normal (ULN) OR direct bilirubin normal (per institute standards)

9. Aspartate aminotransferase (AST) =< 1.5 x ULN; alanine aminotransferase (ALT) and AST =< 3 x ULN is acceptable if there is liver metastasis

10. Fertile patients must use adequate contraception

Exclusion Criteria:

1. Whole-brain radiotherapy (WBRT) < 14 days from the anticipated start of nicorandil/placebo administration

2. Unable to start nicorandil/placebo treatment between 4 - 6 weeks after completing the last dose of thoracic radiation

3. Active untreated brain or leptomeningeal metastases; in patients with treated central nervous system (CNS) metastases, eligible if symptoms controlled for at least 4 weeks; dexamethasone allowed if total daily dose does not exceed 2 mg

4. Major injuries or surgery (e.g., craniotomy) < 28 days from the start of nicorandil/placebo administration; wound should be healed prior to starting therapy

5. Second malignancies are allowed as long as the disease does not require active treatment with concomitant systemic cytotoxic chemotherapy, investigational or biologic therapy (e.g., anti-cytotoxic T-lymphocyte-associated protein 4 [CTLA4] or human epidermal growth factor receptor 2 [HER2] monoclonal antibodies); hormone-related therapies (e.g., gonadotrophin releasing hormone (LHRH) agonists, tamoxifen, etc.) are allowed

6. Concurrent uncontrolled illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situation that would increase the risk associated with study participation and/or limit compliance with study requirements

7. Common Terminology Criteria for Adverse Events (CTCAE) Grade 2 or higher proteinuria

8. Systemic therapy or investigational agent administered < 28 days prior to treatment with nicorandil

9. Pregnancy or breast feeding; female patients with child-bearing potential must have a negative pregnancy test (beta-human chorionic gonadotropin [B-HCG] test in urine or serum) prior to commencing study treatment

10. Creatinine > 1.5 x ULN or creatinine clearance levels (CrCL) < 45 mL/min

11. Centrally located tumors with radiographic evidence (computed tomography [CT] or magnetic resonance imaging [MRI]) of local invasion of major blood vessels

12. acute myocardial infarction within 2 weeks before percutaneous coronary intervention

13. contraindications to treatment with nicorandil (allergy, glaucoma, digestive ulcer, is currently taking phosphodiesterase-5 inhibitor)

14. bypass restenosis

15. PCI history

16. hypotension

17. impaired liver function

18. renal insufficiency requiring hemodialysis

19. pregnancy

20. connective tissue disease

21. life expectancy = 12 months

22. left main coronary artery disease

23. bypass graft lesion and lesions unsuitable for OCT

24. unwillingness or inability to provide informed consent

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Drug:
Nicorandil
oral intake

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Taipei Medical University WanFang Hospital

Outcome

Type Measure Description Time frame Safety issue
Primary The rate of symptomatic radiation pneumonitis in patients with unresectable Stage II/III/ oligometastatic IV non-small cell lung carcinoma (NSCLC) who completed chemoradiation followed by nicorandil or not Up to 2.5 years post-treatment Yes
Secondary The quality of life (QOL) questionnaire Baseline up to 2.5 years post-treatment Yes
Secondary Biomarker analysis such as TGF-ß, Serum surfactant proteins-A & -D, MMP1 and MMP7 Up to 97 days post-treatment Yes
Secondary The overall survival in patients who received nicorandil versus observation Up to 2.5 years post-treatment Yes
Secondary Radiation pneumonitis (RP) score in patients who received nicorandil versus observation Baseline up to 2.5 years post-treatment Yes
Secondary The composite index (based on PFT, RP score and QOL) at the end of active treatment and 6 months after completion of treatment between patients who received nicorandil versus observation. Baseline up to 2.5 years post-treatment Yes
Secondary Responses rates Up to 2.5 years post-treatment Yes
See also
  Status Clinical Trial Phase
Recruiting NCT02490319 - Study on the Biological Prediction Models of Radiation Pneumonitis
Recruiting NCT03803787 - Prophylactic Inhaled Steroids to Reduce Radiation Pneumonitis Frequency and Severity in Lung Cancer Patients Phase 2
Completed NCT03796364 - Clinical Study of Endostatin in Improving Radiation Pneumonia and Fibrosis Phase 2
Not yet recruiting NCT04632342 - Phase 2a Clinical Trial to Evaluate the Efficacy and Safety of HL301 on Radiation Pneumonitis in Non-small Cell Lung Cancer Patients Phase 2
Recruiting NCT05365802 - FAPI PET for Lung Fibrosis Early Phase 1
Completed NCT01754909 - Mitigation of Radiation Pneumonitis and Fibrosis Phase 2
Recruiting NCT05189496 - Hyperbaric Oxygen in the Prevention of Radiation Pneumonitis N/A
Completed NCT01745484 - Role of SPECT in Radiotherapy of Lung Cancer and Toxicity Evaluation N/A
Recruiting NCT00155909 - Risk Factors of Radiation Pneumonitis N/A
Recruiting NCT06069115 - Radiotherapy Exposed Lung Injury: Effect on Functioning - Cohort
Not yet recruiting NCT02296281 - Safety and Efficacy Study of Pirfenidone to Treat Grade 2 or Above Radiation-induced Lung Injury Phase 2
Completed NCT04863027 - Use of Dual Energy Computed Tomography in Thoracic Radiotherapy Planning.
Completed NCT03462524 - Neoadjuvant Therapy for Esophageal Cancer and Cardiopulmonary Physiology N/A
Recruiting NCT05448703 - A Study on Predictive Models and Clinical Outcome of Radiation Pneumonitis
Recruiting NCT06079931 - The Efficacy of Babaodan Capsules in Preventing Radiation Pneumonia Phase 2
Recruiting NCT04676828 - Functional Lung Avoidance SPECT-guided Radiation Therapy of Lung Cancer N/A
Recruiting NCT02735746 - Novel Lung Imaging in Adults Undergoing Radiation Therapy to Assess for Radiation Pneumonitis